Trending
PNC-27
Penetratin-linked peptide corresponding to the p53 MDM2-binding domain. Studied for selective induction of apoptosis in cancer cells expressing
Anti-Aging
● In Stock
Buy more, save more
—
1+ vials
−5%
3+ vials
−10%
5+ vials
−20%
10+ vials
Total Price
$170
For research & laboratory use only. Not for human consumption.
Half-Life
Unknown
Administration Route
Subcutaneous injection
Cancer Cell Specific
MDM-2 binding peptide selectively induces cancer cell apoptosis
Healthy Cell Safety
Does not affect non-cancerous cells lacking MDM-2 overexpression
p53 Pathway Activation
Restores tumour suppressor p53 function in malignant cells
Effect Profile
Based on primary research mechanisms
Cellular Longevity
0%
Collagen Synthesis
0%
Oxidative Protection
0%
Energy Restoration
0%
Mechanism of Action
PNC-27 contains a sequence corresponding to residues 12-26 of p53 linked to a penetratin cell-penetrating peptide. It is proposed to bind membrane-bound HDM2 (human double minute 2) expressed on the surface of cancer cells, disrupting the cancer cell membrane. The interaction triggers pore formation in the membrane of HDM2-expressing tumour cells, inducing cell death. Normal cells express HDM2 intracellularly but not on the membrane surface, providing selectivity for transformed cells.
Scientific Research
1
The p53-targeting compound PNC-27 kills cancer cells by penetrating cell membranes and forming pores
Journal of Biological Chemistry (2012)
